Navigation Links
Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/6/2009

BASKING RIDGE, N.J., Jan. 6 /PRNewswire/ -- Regado Biosciences, Inc. announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2009, at 11:30am Pacific Time (2:30pm Eastern Time). Dr. Mazzo's presentation will include a review of the Company's lead compound in development, the REG1 System, its pipeline and enterprise-level business initiatives.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system is comprised of an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. This technology is being applied to acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect providing a safe and unique approach to personalized medicine.

Regado's lead program, the REG1 System, is comprised of two parenteral agents, the first being a potent and highly selective Factor IXa inhibitor and the second being its complementary reversal agent which can be used to completely or selectively lower the anticoagulant effects. The REG1 System is currently in Phase 2 clinical testing.


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
2. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
3. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
4. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
5. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
6. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
8. Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System
9. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
10. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
11. Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Kathy ... President of Clinical Operations. She brings years of expertise in establishing and leading ... professional foundation as a licensed occupational therapist, through a variety of leadership roles ...
(Date:5/23/2017)... Boston, Massachusetts (PRWEB) , ... May 23, 2017 , ... ... is making a splash at this year’s Bio-IT World Conference and Expo ... Anzo Smart Data Lake® 4.0 solution. The Anzo Smart Data Lake is also ...
(Date:5/22/2017)... ... , ... Stratevi, a boutique firm that partners with healthcare companies to creatively ... office in downtown Boston at 745 Atlantic Ave. , “We are seeing that ... on the value they provide, not just to patients, but also payers. Having a ...
(Date:5/22/2017)... PA (PRWEB) , ... May 22, 2017 , ... ... announced today that it is exhibiting in booth B2 at the Association for ... Pittsburgh, May 22-25. , In addition to demonstrating its Cancer Diagnostic Cockpit ...
Breaking Biology Technology:
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):